Evidence map›Paper›PMID 42154273›Full record

ArticleAnnals of hematology2026

Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: a monocentric study.

Nicolas Thomas Iannozzi, Gabriella Sammarelli, Andrea Poletti, Giannalisa Todaro, Matia Bernardi, Matteo Scita, Anna Benedetta Dalla Palma, Vincenzo Raimondi, Oxana Lungu, Eleonora Carboni and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nicolas Thomas Iannozzi *Laboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Gabriella Sammarelli *Hematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Andrea PolettiLaboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Giannalisa TodaroHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Matia BernardiHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Matteo ScitaHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Anna Benedetta Dalla PalmaHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Vincenzo RaimondiLaboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Oxana LunguLaboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Eleonora CarboniHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Stefania RicciHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Camilla SitziaLaboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Mattia DessenaLaboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Rosanna VescoviniLaboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Denise ToscaniHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Paola StortiLaboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Nicola GiulianiLaboratory of Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy. nicola.giuliani@unipr.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of chromosome 1 abnormalities in multiple myeloma (MM) has been included in the more recent prognostic staging system; however, the prognostic role of chromosome 1 abnormalities remains controversial. Thus, in this study we have investigated the prognostic role of chromosome 1 abnormalities in a cohort of newly diagnosed MM (NDMM), performing a retrospective monocentric analysis of 95 patients. Median follow up was 66 months for overall survival (OS) and progression free survival (PFS), and 55 months for time to next treatment (TTNT). Univariate analyses showed that 1q gain or amplification did not significantly affect outcomes (OS p=0.30; PFS p=0.69; TTNT p=0.91). Conversely, del(1p) was associated with inferior OS (p=0.015), PFS (p=0.007), and TTNT (p=0.038), although this effect did not persist in multivariable models. Notably, the co occurrence of del(1p) and del(17p) identified a subgroup with markedly worse prognosis across all endpoints and represented the only combination with a consistent additive adverse effect. Multivariable analyses confirmed that patients harboring both abnormalities had significantly poorer outcomes, including reduced OS (HR 6.97, 95% CI 2.94-16.54), PFS (HR 6.92, 95% confidence interval [CI] 2.89-16.55), and TTNT (HR 5.21, 95% CI 1.69-16.05. In conclusion, our study suggests that among the cytogenetic abnormalities, del(1p) is a significant negative prognostic factor in NDMM patients in combination with the presence of del(17p), in shaping the prognosis of NDMM.

Indexed as

Chromosome AberrationsChromosomes, Human, Pair 1Multiple MyelomaAdultAgedAged, 80 and overChromosome DeletionChromosomes, Human, Pair 17Disease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesCytogenetic abnormalitiesMultiple myelomaPrognosisSurvival

Identifiers

PMID42154273
PMCPMC13350107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.